Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-DF vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and blocking adenosine receptors.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/m L.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life: 3–12 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours), congestive heart failure, and in neonates; also prolonged in elderly and patients with fever or viral illness. Half-life is shorter in smokers (4–5 hours).
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4; first-pass metabolism; ~90% metabolized, <10% excreted unchanged.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal excretion of unchanged drug: approximately 10%; hepatic metabolism accounts for >90% of elimination; metabolites are excreted renally. Less than 5% eliminated in feces.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
Apparent volume of distribution: 0.45 L/kg; distributes freely into body water, with higher distribution in neonates and patients with liver disease.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 96–100%; oral extended-release (Somophyllin-DF): 80–100% relative to intravenous, with reduced absorption due to slower release.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No dose adjustment required for renal impairment. However, monitor serum levels in patients with renal failure receiving theophylline as metabolites may accumulate.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class A: Reduce dose by 50%. Child-Pugh Class B: Reduce dose by 60-75%. Child-Pugh Class C: Reduce dose by 80-90%. Monitor serum levels closely.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Oral: Initial 16 mg/kg/day or 400 mg/day (whichever is less) in divided doses every 12 hours; extended-release. Adjust based on serum levels. Maximum 20 mg/kg/day or 800 mg/day.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Elderly patients: Start at lower end of dosing range, 300-400 mg/day in divided doses. Monitor serum levels frequently due to decreased clearance.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Cardiovascular toxicity (arrhythmias), seizure risk, hypersensitivity reactions, interactions with fluoroquinolones and macrolides, smoking cessation reduces clearance, monitor serum theophylline levels.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or xanthines, active peptic ulcer disease, uncontrolled seizure disorders.
Hypersensitivity to theophylline or any component of the formulation.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate, energy drinks) as it can increase stimulant effects and risk of toxicity. Charcoal-broiled foods may increase metabolism of theophylline, potentially reducing effectiveness. High-protein/low-carbohydrate diets may reduce clearance; high-carbohydrate/low-protein diets may increase clearance. Grapefruit juice does not significantly interact, but consistent intake pattern is advised.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline (SOMOPHYLLIN-DF) is not a major human teratogen. First trimester: Retrospective studies show no significant increase in congenital anomalies, but data are limited. Second/third trimester: Fetal tachycardia, irritability, and jitteriness can occur due to transplacental passage; risk of neonatal withdrawal if used near term. Avoid high doses near delivery.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with a milk-to-plasma ratio approximately 0.67. Infant serum levels can reach therapeutic or toxic concentrations, especially in preterm or neonatal infants. Caution advised; monitor infant for irritability or poor feeding. Use only if clearly needed.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Clearance of theophylline decreases in the third trimester due to reduced hepatic metabolism. Doses may need reduction by 20-30% compared to non-pregnant state, guided by trough serum concentrations. Increase monitoring frequency (every 1-2 weeks) during dose adjustments.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Verify controlled-release properties: do not crush or chew tablets. Monitor theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Use with caution in patients with CHF, hepatic impairment, or febrile illness as clearance may decrease. Cigarette smoking increases clearance; adjust dose accordingly. Concurrent use with cimetidine, fluoroquinolones, or macrolides can significantly increase levels.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not skip doses or double up. Swallow tablets whole—do not crush or chew. Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects. Report symptoms of toxicity: persistent nausea, vomiting, insomnia, jitteriness, or rapid heart rate. Do not smoke or stop smoking without telling your doctor; smoking changes how this medicine works. Keep all appointments for blood tests to check drug levels. Store at room temperature, away from moisture and heat.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOMOPHYLLIN-DF vs AEROLATE JR, answered by our medical review team.
SOMOPHYLLIN-DF is a Bronchodilator that works by Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and blocking adenosine receptors.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOMOPHYLLIN-DF and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOMOPHYLLIN-DF is: Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOMOPHYLLIN-DF and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOMOPHYLLIN-DF is classified as Category C. Theophylline (SOMOPHYLLIN-DF) is not a major human teratogen. First trimester: Retrospective studies show no significant increase in congenital anomalies, but data are limited. Sec. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.